Latest News

It was a busy 2015 for Aagami with 5 deals for its various clients, several consulting assignments, few market intelligence assignments, a lot of travel within and outside US, and fortification of Aagami team with a partner level resource with global experience and expertise.

We are happy to share this roundup of the year gone by and looking forward to your continued support in 2016 and beyond. 

Highlights of 2015:

Client projects

We worked with new clients as well as got new assignments from existing /past clients. 

Strategic Consulting / Licensing / Partnering

  1. Out-Licensing of a Novel Anti-infective drug

    Partnership established for Canada. Term Sheet signed for US market.

  2. Establishing Distribution channel in India for a US based Labware Consumables Company

    Completed for South India and West India.

  3. Investment for development of therapies and vaccines of a oncology focused Louisiana Biotech Company 

    Facilitated Listing on OTC Markets using reverse merger resulting in Line of Credit (US$ 10mn).

  4. Out-licensing of Transdermal Drug Delivery Technology for a Public listed Company from Australia

    Several companies in advanced discussions including term sheet.

  5. Partnerships for a US client’s innovative technology for poorly soluble & heat-sensitive APIs

    Several companies in advanced discussions.

  6. Develop a 5 year strategy plan for a Natural Medicines & Herbal Ingredients company

    Started late 2015 and Ongoing.

  7. Licensing of Innovative vector tools to improve mammalian cell-based expression systems of a Norwegian company

    In discussions with several interested parties from India, Rest of Asia and Latin America.

Market Intelligence

  1. Market Study to Identify Acquisition Targets for a Global Leader in medical equipment and integrated solution for patients
  2. Competitive Landscape Assessment of Derma and Pain market for India Strategy of a technology development company of New Zealand
  3. Aagami Expert Speak: Great opportunity for India based Global companies: (Latin America on Sale:)
  4. Note on Mental Health (Especially Depression) in India (with facts and figures)
  5. A report on Select cross border deals in Life Sciences (2014-15) where Indian companies were involved ( Please feel free to ask for a complimentary copy).

Business development and networking

Jan 2015 – JP Morgan Healthcare and Biotech Showcase 2015 – 45+ meaningful meetings; enjoyed representing clients while also promoted Aagami services for New Business.

Jan 2015 – iBIO Co-founder and ‘Cures Within Reach’ Award winner Michael S Rosen joins Aagami as Partner Consultant.

Feb 2015 – Bangalore INDIA BIO 2015 – Represented several clients, got deals closed during the event, while also getting new business

March 2015 - Nutra India Summit – Represented a NZ PharmaNatural technology company 26 meetings to discuss licensing model while another 15 meetings to discuss Sales & Distribution model.

May 2015 - Aagami CEO and Partner Consultant made Presentation at Life Science Summit organised by Consulate General of India - Chicago.

June 2015 - BIO International Convention at Philadelphia; 50+ pre-arranged one on one business meetings for Aagami and its clients.

July 2015 - Dinesh Jain and Michael Rosen made presentations and co-chaired sessions at US-India Healthcare Summit in Minneapolis, Minnesota.

August 2015 - Business trip to India along with a New Zealand based Client for advanced discussions with the interested companies.

Nov 2015 – BIO Europe in Munich; 35+ pre-arranged business meetings with C level executives around the globe for Aagami and its clients.

Dec 2015 - Business Trip to India to represent a Texas based client. 10+ pre-arranged business meetings with C level executives in the Pharma industry.

We want to thank each of our business associates and friends like you, who have been with us all this while. Please accept our sincere gratitude as we look forward to working and sharing together again in 2016 and beyond.

Aagami successfully facilitated Investments and partnering for an oncology focused Louisiana Biotech Company. This has enabled them to further develop their technologies and pipeline of targeted therapies and therapeutic vaccines.

Client is a clinical-stage bio-pharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. They have a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. They are headquartered in Baton Rouge, LA, US.

Solution Approach

  • Aagami scanned the global market, identified right investors/ partners, and took them to 50 + companies.
  • With focused efforts 10+ companies had post CDA level scientific and clinical discussions.
  • Aagami kept facilitating and persevering, 3 companies moved to term sheet level discussions.
  • Finally Aagami found a right partner to facilitate reverse merger with a OTC Markets listed company.
  • This is enabling access to large sums of funds to develop clinical stage programs.



  • Listing on OTC Markets by a reverse merger
  • Financial resources to enable development of existing pipeline and technologies.

Aagami is to study the Natural Medicines and Natural ingredients (Herbal Extracts) market in the US, and develop a target based 5 year strategy plan, for an India based company.


Aagami has signed up with another new client in the US. Client has a unique technology to enhance solubility.
Since its inception, various applications for client’s technology platform have been established in the field of drug delivery. 


Aagami has a new client. This time, it’s a broad assignment from a Norway based company with Innovative tools to further improve mammalian cell-based expression systems.


In the earlier assignments Aagami facilitated deals with 3 global companies of India, for their Australian client. Also couple of assignments involving market research and vendor sourcing were also executed in last 2 years.

Client has yet again placed their trust in Aagami and have assigned Aagami for further partnerships for Dermal Delivery technology and their pipeline assets in derma, pain and anaesthetic.


Aagami has successfully delivered yet another assignment.

Licensing agreement done for Client’s Novel Antibiotic Product Drug for Canada. Client Partner will register the product and sell exclusively in Canada. Aagami looks forward to repeating the success for US region as well.


The Consulate General India - Chicago is organising a Life Science Summit on May 18, 2015 between 11:30am to 3:30pm. The Venue is 455 North Cityfront Plaza Drive, 8, NBC Tower, Chicago, IL 60611


Aagami CEO, Dinesh Jain, is participating in the 2015 BIO International Convention which will be held in Philadelphia, Pennsylvania (June 15-18).

This Annual event is the world’s largest biotechnology gathering. Aagami will utilise the BIO One-on-One Partnering™ system which increases partnering effectiveness.


An Indian private limited Biotech company has appointed Aagami to help them find the right Strategic Investor or Joint Venture Partner, to commercialise their patented technology for manufacturing Algal DHA.


10th Nutra India Summit was held from March 18-19, 2015 at Hotel Lalit, Mumbai. Godwyn Francis, Head of Business Development at Aagami, represented its New Zealand client which is a Technology development company in OTC PharmaNaturals.


Keeping the trust of its Illinois based Lab Consumables client, Aagami has successfully helped establish Distribution channel for client in Western and Southern India.